Vericel Corporation (VCEL)

Business: Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States.

IPO Date: 04-Feb-1997

CEO, Pres & Director: Mr. Dominick C. Colangelo Esq.

CFO & Treasurer: Mr. Joseph Anthony Mara Jr.

Listing: NASDAQ: VCEL

Country: United States

Headquarters: Cambridge, MA

Website: https://vcel.com

Market cap: $1,451.67 Mln

Revenue (TTM): $157.69 Mln

Earnings (TTM): $-11.27 Mln

Cash: $100.55 Mln

Total Debt: $49.26 Mln

Insider's Holding: 0.71%

Liquidity: Low

52 Week range: $22.42 - 60.24

Shares outstanding: 47,119,900

10 Years Aggregate:

• CFO: $-82.30 Mln
• EBITDA: $-132.99 Mln
• Net Profit: $-140.62 Mln